Page last updated: 2024-12-04

3-hydroxybutyric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(R)-3-hydroxybutyric acid : The R-enantiomer of 3-hydroxybutyric acid. Involved in the synthesis and degradation of ketone bodies, it can be used as an energy source by the brain during hypoglycaemia, and for the synthesis of biodegradable plastics. It is a sex pheremone in the European spider Linyphia triangularis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID92135
CHEMBL ID1162484
CHEBI ID17066
SCHEMBL ID60959
MeSH IDM0029884
PubMed CID441
CHEMBL ID1162496
CHEBI ID20067
SCHEMBL ID2731
MeSH IDM0029884

Synonyms (166)

Synonym
gtpl1593
beta-d-hydroxybutyric acid
(r)-(-)-beta-hydroxybutyric acid
CHEBI:17066 ,
3-d-hydroxybutyric acid
d-3-hydroxybutyric acid
(3r)-3-hydroxybutanoic acid
625-72-9
C01089
(r)-3-hydroxybutanoic acid
(r)-3-hydroxybutanoate
d-beta-hydroxybutyric acid
(r)-3-hydroxybutyric acid
LMFA01050243
(r)-beta-hydroxybutyric acid
3r-hydroxy-butanoic acid
(r)-(-)-3-hydroxybutyric acid
butyric acid, 3-hydroxy-, d-(-)-
(r)-beta-hydroxybutanoic acid
(-)-3-hydroxy-n-butyric acid
(r)-3-
(-)-3-hydroxybutyric acid
butanoic acid, 3-hydroxy-, (r)-
H-4010
3-(r)-hydroxybutyric acid
MLS001333960
smr000857294
(r)-3-hydroxybutyric acid, >=98.0% (t)
CHEMBL1162484 ,
A833857
(r)-3-hydroxybutyric acid;(r)-3-hydroxybutanoic acid
NCGC00246976-01
3hr ,
HMS2230E08
(-)-beta-hydroxybutyrate, d-
3-hydroxybutanoic acid, (r)-
unii-148ulj1df4
148ulj1df4 ,
einecs 210-909-6
S3320
bdbm50412190
SCHEMBL60959
d-(-)-3-hydroxybutyrate
d-(-)-.beta.-hydroxybutyric acid
3-hydroxybutyric acid, (r)-
.beta.-hydroxybutyric acid l-form [mi]
3-hydroxybutyric acid, (r)
butanoic acid, 3-hydroxy-, (3r)-
AKOS016843355
butanoic acid,3-hydroxy-, butyl ester, (3r)-
mfcd00066257
DTXSID3041829
(r)-3-hydroxybutanoicacid
b-hydroxybutyrate
delta-3-hydroxybutyric acid
(r)-(-)-b-hydroxybutyrate
bhib
delta-(-)-3-hydroxybutyrate
delta-3-hydroxybutyrate
3-delta-hydroxybutyrate
3-delta-hydroxybutyric acid
(r)-(-)-b-hydroxybutyric acid
delta-beta-hydroxybutyrate
HY-W051723
r-3-hydroxybutanoic acid
DS-18570
Q27075135
AMY24176
CS-0044101
O10175
EN300-151274
AC-5701
625-71-8
nsc-3806
.beta.-hydroxybutyric acid
butyric acid, 3-hydroxy-
nsc3806
butanoic acid, 3-hydroxy-
300-85-6
.beta.-hydroxy-n-butyric acid
3-hydroxybutyric acid
3 hba
3-hydroxybutanoic acid
beta-hydroxy-n-butyric acid
dl-beta-hydroxybutyric acid
CHEBI:20067 ,
beta-hydroxybuttersaeure
3-oh-butyric acid
3-hydroxybuttersaeure
beta-hydroxybutanoic acid
(1)-3-hydroxybutyric acid
bhba
beta-hydroxybutyric acid
3-hydroxy-butanoic acid
LMFA01050005
d(-)-beta-hydroxy butyric acid
3-hydroxybutyric acid, 95%
(+-)-3-hydroxybutyric acid
smr000112209
MLS001332398
MLS001332397
869DD3C9-3114-4BE2-B4A6-6F1787476E95
BMSE000161
butyric acid, 3-hydroxy- (8ci)
ai3-21675
dl-3-hydroxybutyric acid
H0228
CHEMBL1162496
d,l-3 hydroxybutyrate
beta-hydroxy-butyrate
3-hydroxybutyric acid, (+/-)-
hydroxybutyric acid, dl-
26063-00-3
A833855
AKOS009156821
BMSE000905
HMS2270C20
nsc 3806
einecs 206-099-9
unii-tzp1275679
tzp1275679 ,
einecs 210-908-0
FT-0605325
FT-0605155
FT-0625402
FT-0615836
STL377875
S1031
HMS3369F13
BBL027467
3-hydroxy-butyric acid
3- hydroxybutyric acid
SCHEMBL2731
beta-hydroxybutyric acid [who-dd]
3-hydroxybutyric acid [inci]
(+/-)-3-hydroxybutyric acid
(+/-)-3-hydroxybutanoic acid
.beta.-hydroxybutyric acid [mi]
.beta.hydroxybutyric acid
mfcd00004546
poly(3-hydroxybutyric acid)
3-hydroxybutyricacid
(.+/-.)-3-hydroxybutyric acid
dl-.beta.-hydroxybutyric acid
HB4640
EN300-147463
J-016241
J-017776
CS-0062335
HY-113378
DTXSID60859511
VS-08544
(rs)-3-hydroxybutyric acid
Q223092
AMY10050
(+/-)-beta-hydroxybutyrate
D84191
A876308
SB44475
AB88579
SY076545
dl-3-hydroxybutyricacid
butanoic acid, 3-hydroxy-, (a+/-)-
3-hydroxybutyric acid, tech grade
SY114480
SY074781

Research Excerpts

Overview

3-Hydroxybutyric acid (3HB) is a ketone body. It acts as an indicator of energy balance and a central regulator of energy homeostasis.

ExcerptReferenceRelevance
"3-Hydroxybutyric acid (3HB) is a ketone body and acts as an indicator of energy balance and a central regulator of energy homeostasis. "( Enzymatic fluorometric microplate assay for quantitative analysis of 3-hydroxybutyric acid in mouse plasma.
Ohara, T; Takayama, N; Yamamoto, N, 2012
)
2.06

Toxicity

ExcerptReferenceRelevance
" Three double-blind studies examined the safety of the combination of HMB, arginine and glutamine on blood chemistries, hematology, emotional profile, and adverse events."( Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters.
Abumrad, NN; Barber, AE; Clark, RH; D'Olimpio, J; Eubanks May, P; Nissen, S; Panton, L; Rathmacher, JA,
)
0.13
"Across the 3 studies, HMB, arginine, and glutamine supplementation was not associated with any adverse indicators of health."( Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters.
Abumrad, NN; Barber, AE; Clark, RH; D'Olimpio, J; Eubanks May, P; Nissen, S; Panton, L; Rathmacher, JA,
)
0.13
"Recently developed understanding of the mechanisms, efficacy, and safety of niacin, along with progress in reducing the chief side effect of flushing, should enhance the use of this valuable agent for cardiovascular prevention."( Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.
Guyton, JR, 2007
)
0.34
" It was determined that ketone bodies such as beta-hydroxybutyrate and acetoacetate were important in separating the toxic from the nontoxic phenotypes."( Using dynamic gene module map analysis to identify targets that modulate free fatty acid induced cytotoxicity.
Chan, C; Findlan, R; Li, Z; Srivastava, S,
)
0.13
"Thallium (Tl) is a toxic heavy metal and its exposure to the human body causes physiological and biochemical changes due to its interference with potassium-dependent biological reactions."( Study of acute biochemical effects of thallium toxicity in mouse urine by NMR spectroscopy.
Bhatnagar, D; Chaturvedi, S; Devi, MM; Khan, AR; Khushu, S; Rana, P; Tripathi, RP; Tyagi, R, 2011
)
0.37
"Systems that suspend basal insulin for 2 h are safe and do not lead to clinically significant ketonemia even if the blood glucose level is elevated at the time of the suspension."( Safety of nighttime 2-hour suspension of Basal insulin in pump-treated type 1 diabetes even in the absence of low glucose.
Carria, L; Cengiz, E; Michaud, C; Palau Collazo, M; Sherr, JL; Steffen, AT; Tamborlane, WV; Tichy, E; Weinzimer, SA; Weyman, K; Zgorski, M, 2014
)
0.4
"A simple and highly safe poly(3-hydroxybutyrate-co-R-3-hydroxyhexanoate) nanoparticulate delivery system that targets different cell types is developed."( Poly(3-hydroxybutyrate-co-R-3-hydroxyhexanoate) nanoparticles with polyethylenimine coat as simple, safe, and versatile vehicles for cell targeting: population characteristics, cell uptake, and intracellular trafficking.
Chen, GQ; Hall, A; Moghimi, SM; Parhamifar, L; Wang, D; Wu, LP, 2014
)
0.4
" D-ß-hydroxybutyrate /M in doses previously shown to be associated with improved survival is safe in a porcine hemorrhagic shock/polytrauma model."( Safety of D-ß-Hydroxybutyrate and Melatonin for the Treatment of Hemorrhagic Shock With Polytrauma.
Asghar, JI; Beilman, GJ; Iyegha, UP; Mulier, KE; Wolf, A, 2015
)
0.42
" The present study suggested that 1% D-3-hydroxybutyrate eye drops are safe and effective in treating ocular surface disorders in patients with tear-deficient dry eye disease."( Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease.
Arai, H; Fukagawa, K; Hata, S; Kawakita, T; Okano, T; Sakatani, K; Shimazaki, S; Tanaka, M; Toda, I; Tsubota, K; Uchino, M; Yoshino, K, 2016
)
0.43
"The strength of the current study is the international pooling of data demonstrating that D,L-3-HB treatment can be effective and safe in MADD(-like) patients."( Efficacy and safety of D,L-3-hydroxybutyrate (D,L-3-HB) treatment in multiple acyl-CoA dehydrogenase deficiency.
Aktuğlu Zeybek, AÇ; Allersma, DP; Bhattacharya, K; Debray, FG; Derks, TGJ; Ellaway, CJ; Gautschi, M; Geraghty, MT; Gil-Ortega, D; Jager, EA; Larson, AA; Moore, F; Morava, E; Morris, AA; Oishi, K; Schiff, M; Scholl-Bürgi, S; Tchan, MC; Van Hove, JLK; van Rijt, WJ; van Spronsen, F; Vockley, J; Witters, P; Wortmann, SB, 2020
)
0.56
" We conclude that supplementing with exogenous beta-hydroxybutyrate salts is safe and well-tolerated by healthy adolescents."( The Effect of Exogenous Beta-Hydroxybutyrate Salt Supplementation on Metrics of Safety and Health in Adolescents.
Gheith, R; Lowery, R; Sharp, M; Stefan, M; Wilson, J, 2021
)
0.62
" To be used by humans, TCN006 must be determined safe in appropriately designed safety studies."( Toxicity Investigations of (R)-3-Hydroxybutyrate Glycerides In Vitro and in Male and Female Rats.
Arceneaux, BG; Chesne, AM; Dolan, LC; Karikachery, AR; Katti, KK; Katti, KV; Thipe, VC, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" Under the graphically measured half-life of 17 minutes for the MCT/LCT emulsion, rapid and complete elimination could be seen after the infusion had been stopped."( [Pharmacokinetic studies of a new 20% fat emulsion containing 70% medium-chain triglycerides].
Kleine, R; Lessire, H; Mertes, N; Pfisterer, M; Puchstein, C; Winde, G; Zander, J, 1990
)
0.28
" Furthermore, the plasma oxipurinol half-life was increased from 27."( Sustained reductions in oxipurinol renal clearance during a restricted diet.
Berlinger, WG; Kitt, TM; Park, GD; Spector, R; Tsalikian, E, 1987
)
0.27
" Administration of SPA at different rates and doses (60 microg kg[-1] in 5 min and 15 min, and 120 microg kg[-1] in 60 min) led to uniform pharmacodynamic parameter estimates."( Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N6-(p-sulphophenyl)adenosine in rats.
Danhof, M; de Greef, HJ; IJzerman, AP; Langemeijer, MW; Sheehan, MJ; van Schaick, EA, 1997
)
0.3

Compound-Compound Interactions

ExcerptReferenceRelevance
"To compare relative efficacy of dexamethasone and flumethasone alone or in combination with rapid IV infusion of glucose for treatment of ketosis in cattle."( Use of corticosteroids alone or combined with glucose to treat ketosis in dairy cows.
Avidar, Y; Bogin, E; Chen, R; Shpigel, NY, 1996
)
0.29
" When acetoacetate, beta-hydroxybutyrate, or KIC were combined with MMS, or either ketone body was combined with lactate, insulin release was stimulated 10-fold to 20-fold the controls (almost as much as with glucose)."( Acetoacetate and beta-hydroxybutyrate in combination with other metabolites release insulin from INS-1 cells and provide clues about pathways in insulin secretion.
Brown, LJ; Hasan, NM; Kendrick, MA; Longacre, MJ; MacDonald, MJ; Stoker, SW, 2008
)
0.35
" The diagnostic model is, in our opinion, valuable for herd-level monitoring of hyperketonemia, especially when the model is combined with wet chemistry analysis of milk acetone or milk BHBA concentrations."( Routine detection of hyperketonemia in dairy cows using Fourier transform infrared spectroscopy analysis of β-hydroxybutyrate and acetone in milk in combination with test-day information.
Jorritsma, R; Knijn, HM; Schonewille, JT; Stegeman, JA; van der Drift, SGA, 2012
)
0.38
"Here, we report an analysis method for determining PHA (polyhydroxyalkanoates) contents and their monomer composition in microbial cells based on pyrolysis gas chromatography combined with mass spectrometry (Py-GC/MS)."( Rapid analysis of polyhydroxyalkanoate contents and its monomer compositions by pyrolysis-gas chromatography combined with mass spectrometry (Py-GC/MS).
Jeon, SG; Khang, TU; Kim, MJ; Na, JG; Park, SJ; Sohn, YJ; Yoo, JI, 2021
)
0.62
" Interestingly, the -N cultivation combined with 2-phenylethanol exposure reduced the Synechocystis protein content by 27% (w/w DW) but significantly increased PHB levels up to 33% (w/w DW), the highest ever reported photoautotrophic cyanobacterial PHB accumulation in a wild-type strain."( Chemicals Affecting Cyanobacterial Poly(3-hydroxybutyrate) Accumulation: 2-Phenylethanol Treatment Combined with Nitrogen Deprivation Synergistically Enhanced Poly(3-hydroxybutyrate) Storage in Synechocystis sp. PCC6803 and Anabaena sp. TISTR8076.
Incharoensakdi, A; Monshupanee, T; Sukkasam, N, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" However, plasma levels of carnitine and the rate of urinary elimination of carnitine both after treatment and after an acute oral load were increased before and after surgery, indicating that carnitine was well absorbed by the shortened gut."( Oral L-carnitine administration after jejunoileal by-pass surgery.
Burget, D; Cleator, I; Frohlich, J; Gourlay, RH; Hahn, P; Seccombe, D, 1984
)
0.27
" These issues are being addressed by designing and synthesizing orally bioavailable multimers of betaOHB with improved pharmacokinetics."( KTX 0101: a potential metabolic approach to cytoprotection in major surgery and neurological disorders.
Heal, DJ; Martin, KF; Smith, SL, 2005
)
0.33
" Results demonstrate that SNEB affects hepatic synthesis of IGF-I, and other components known to modulate the bioavailability and stability of circulating IGF-I."( Interrelationships between negative energy balance (NEB) and IGF regulation in liver of lactating dairy cows.
Diskin, MG; Fenwick, MA; Fitzpatrick, R; Kenny, DA; Murphy, JJ; Patton, J; Wathes, DC, 2008
)
0.35
" In comparison to the non-conjugated drug in oily solution, the relative bioavailability of ibuprofen conjugates from oily solution, and o/w emulsion was reduced to 17% and 10%, respectively."( In vivo assessment of parenteral formulations of oligo(3-hydroxybutyric Acid) conjugates with the model compound Ibuprofen.
Ehrhardt, C; Grieb, P; Luczyk-Juzwa, M; Stasiak, P; Sznitowska, M, 2010
)
0.61
" The pharmacological bioavailability (PA) of INS-PLC-NPs relative to insulin solution was over 350%, indicating that the bioavailability of insulin was significantly enhanced by INS-PLC-NPs."( A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles.
Chen, GQ; Gong, T; Peng, Q; Sun, X; Zhang, ZR, 2012
)
0.38
"85%, indicating that the bioavailability of insulin was significantly enhanced by NP-CS/GP gels."( Injectable and biodegradable thermosensitive hydrogels loaded with PHBHHx nanoparticles for the sustained and controlled release of insulin.
Gong, T; Peng, Q; Sun, X; Tan, J; Wu, CY; Zhang, T; Zhang, ZR, 2013
)
0.39
") implantation, its therapeutic effect lasted for over 130 h, and its bioavailability was enhanced by 4-fold."( The implantable and biodegradable PHBHHx 3D scaffolds loaded with protein-phospholipid complex for sustained delivery of proteins.
Gong, T; Peng, Q; Sun, X; Wu, CY; Yang, Q; Yang, YJ; Zhang, L; Zhang, T; Zhang, ZR, 2013
)
0.39
" However, those highly hydrophobic kinase inhibitors shared the common features of poor bioavailability and limited in vivo half-life, which strongly impeded their practical applications."( Microbial synthesized biodegradable PHBHHxPEG hybrid copolymer as an efficient intracellular delivery nanocarrier for kinase inhibitor.
Fan, F; Li, MC; Lu, XY; Ma, JG; Wang, LL; Zhu, XL, 2014
)
0.4
" Finally, we observed that chronic consumption of a high-salt diet negatively regulates both βHB biosynthesis and hepatic autophagy and that reconstitution of βHB bioavailability prevents high-salt diet-induced endothelial dysfunction."( Ketone body β-hydroxybutyrate is an autophagy-dependent vasodilator.
Bearss, NR; Chakraborty, S; Cheng, X; Joe, B; McCarthy, CG; Mell, B; Schreckenberger, ZJ; Singh, A; Singh, G; Vijay-Kumar, M; Wenceslau, CF; Yang, T; Yeoh, BS, 2021
)
0.62
") clearly suppressed the absorption rate and IL-1β production in the placenta induced by LPS in pregnant mice."( β-hydroxybutyrate suppresses NLRP3 inflammasome-mediated placental inflammation and lipopolysaccharide-induced fetal absorption.
Henmi, Y; Hirata, Y; Iwata, H; Karasawa, T; Komiyama, H; Kuwayama, T; Shimazaki, S; Shirasuna, K; Suzuki, S; Takahashi, H; Takahashi, M, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" A plasma glucose level of 300 mg dl-1 was not achieved until the total dosage of insulin amounted to 91,580 units at hour 25."( Transient extreme insulin resistance in shock during diabetic ketoacidosis.
Hasumi, S; Omori, Y; Shimizu, Y; Wasada, T; Yokoyama, H; Yoshino, H, 1992
)
0.28
" To assess the possible dose-response of such short-term bolus administration of GH, six healthy, male subjects were each studied thrice for 4 1/2 hours after an intravenous (IV) bolus of either 70, 140, or 350 micrograms GH, resulting in peak GH concentrations of 10, 15, and 34 micrograms/L."( Dose-response studies on the metabolic effects of a growth hormone pulse in humans.
Jørgensen, JO; Møller, J; Møller, N; Pørksen, N; Schmitz, O, 1992
)
0.28
" Dose-response studies of the glucose-induced release of amylin and insulin revealed that they possessed a similar dependency on glucose."( Release of amylin from perfused rat pancreas in response to glucose, arginine, beta-hydroxybutyrate, and gliclazide.
Hisatomi, A; Inoue, K; Nawata, H; Umeda, F, 1991
)
0.28
" congolensis was assessed by the dose-response to experimental inoculation."( The effect of energy malnutrition in ruminants on experimental infection with Dermatophilus congolensis.
Hill, R; How, SJ; Lloyd, DH; Sanders, AB, 1990
)
0.28
" The system is applicable for oral and parenteral dosage of various drugs."( [Development of press-coated tablets with controlled-release effect with a base of poly-d(-)-3-hydroxybutyric acid].
Korsatko-Wabnegg, B, 1990
)
0.5
" An apparent improvement in utilization of even-MCT was observed between 6 and 18 h, as evidenced by a twofold vs a sixfold increase in 3-OH-butyrate (BHBA) concentration 1 h after dosing and a twofold vs 12-fold increase in plasma fatty acid concentration."( Utilization of medium-chain triglycerides by neonatal piglets: II. Effects of even- and odd-chain triglyceride consumption over the first 2 days of life on blood metabolites and urinary nitrogen excretion.
Benevenga, NJ; Crenshaw, TD; Odle, J, 1989
)
0.28
" Plasma free insulin profiles reflected the dosage patterns and there was no change in insulin metabolic clearance rate in pregnancy."( Observations on the metabolic basis for altered insulin dose distribution in diabetic pregnancy.
Frier, BM; Home, PD; Johnstone, FD; Steel, JM; Young, RJ,
)
0.13
" Ethanol dependence had been induced by intragastric administration of ethanol at a dosage of 9 to 15 grams per kilogram per day over a four-day period."( Suppression of an ethanol withdrawal syndrome in rats by 3-hydroxybutyrate.
Derr, M; Derr, RF, 1985
)
0.27
", it resulted in a leftward shift in the dose-response curve."( beta-Hydroxybutyrate increases the insulin sensitivity of adipocyte glucose transport at a postreceptor level.
Bustillos, DP; Green, A; Misbin, RI, 1984
)
0.27
" It is concluded that high dosed caffeine causes peripheral insulin resistance in the human being as well as in the experimental animal."( [Effect of caffeine on various metabolic parameters in vivo].
Förster, H; Sachs, M, 1984
)
0.27
" Male Sprague-Dawley rats were rendered physically dependent on ethanol by intragastric administration of ethanol at a dosage of 9 to 15 grams per kilogram per day over a 4-day period."( Suppression of an ethanol withdrawal syndrome in rats by butyrate, lactate and beta-hydroxybutyrate.
Derr, M; Derr, RF; Draves, K, 1983
)
0.27
"A method for sampling, for preservation of these samples and for dosage has been studied in order to gain a better knowledge of the usual values and the physiological and pathological variations of beta-hydroxybutyrate and of acetoacetate in the blood and milk of cattle."( [Technical study of hydroxybutyrate and acetoacetate levels in blood and milk of cattle].
André, F; Coppin, F, 1982
)
0.26
"Two experiments were conducted to investigate the causes of the failure of orally dosed medium-chain triglycerides (MCT) in improving the survival of neonatal pigs."( Causes of reduced survival of neonatal pigs by medium-chain triglycerides: blood metabolite and behavioral activity approaches.
Chiang, SH; Lee, HF; Lin, CL, 1995
)
0.29
" The animals receiving the low-fat meal at dosing and at 4 h post-dose exhibited similar extents of absorption, as shown by similar AUC values and urinary radioactivity recovery."( The effect of the fat content of food on the pharmacokinetics and pharmacodynamics of SDZ FOX 988, an antidiabetic agent, in the dog.
Aun, RL; Kalafsky, G; Lau, DT; Tse, FL, 1995
)
0.29
" Earlier basal NPH dosage alone does not ameliorate the nighttime hyperglycemia of short-acting insulin analog regimens."( Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
Ahmed, AB; Home, PD; Mallias, J, 1998
)
0.3
" In conclusion, this study suggests that short-term administration of LA at high dosage to normal and diabetic rats causes an inhibition of gluconeogenesis secondary to an interference with hepatic fatty acid oxidation."( Lipoic acid acutely induces hypoglycemia in fasting nondiabetic and diabetic rats.
Bashan, N; Gutman, A; Khamaisi, M; Potashnik, R; Rudich, A; Tritschler, HJ, 1999
)
0.3
"The present study was designed to establish a dose-response relationship for the efficacy of the ketogenic diet (KD)."( Higher ketogenic diet ratios confer protection from seizures without neurotoxicity.
Bough, KJ; Eagles, DA; Yao, SG, 2000
)
0.31
"5-mg dosage increased plasma insulin only in the multiple-injection experiment."( Metabolic responses of lactating dairy cows to single and multiple subcutaneous injections of glucagon.
Ametaj, BN; Beitz, DC; Bobe, G; Sonon, RN; Young, JW, 2003
)
0.32
"The objective of this experiment was to evaluate whether dose-response effects of intraruminal infusion of propionate on feeding behavior and dry matter intake (DMI) differ by stage of lactation."( Dose-response effects of intrauminal infusion of propionate on feeding behavior of lactating cows in early or midlactation.
Allen, MS; Oba, M, 2003
)
0.32
" Some patients have inadvertently dosed or overdosed while awake or during sleep, causing fatal outcome in rare cases."( Hypoglycemia and ketoacidosis with insulin pump therapy in children and adolescents.
Hanas, R; Ludvigsson, J, 2006
)
0.33
" Animals receiving PG had elevated insulin concentrations over the subsequent 90 min following dosing (P<0."( The effect of feeding propylene glycol to dairy cows during the early postpartum period on follicular dynamics and on metabolic parameters related to fertility.
Boland, MP; Duffy, P; Griffin, W; Kenny, DA; Lonergan, P; Mulligan, FJ; Quinn, KM; Rizos, D; Roche, JF, 2008
)
0.35
" These data suggest that the KD-R and NB-DNJ may be a potential combinatorial therapy for Sandhoff disease by enhancing NB-DNJ delivery to the brain and may allow lower dosing to achieve the same degree of efficacy as high dose monotherapy."( Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
Baek, RC; Bronson, RT; Butters, TD; Denny, CA; Heinecke, KA; Kim, YP; Loh, KS; Platt, FM; Seyfried, TN, 2010
)
0.36
" Blood samples were measured shortly before, and at 8 different time-points after (up to 6 h), the first challenge of each LPS dosage to evaluate the post-challenge plasma profile, as well as weekly up to 4 wk postpartum."( Oral challenge with increasing doses of LPS modulated the patterns of plasma metabolites and minerals in periparturient dairy cows.
Ametaj, BN; Dunn, SM; Mansmann, D; Sivaraman, S; Zebeli, Q, 2013
)
0.39
" On d 2 of FR and d 4 of REC1 and REC3, a 1 L solution of Cr-EDTA (180 mM) was dosed into the rumen followed by 48 h of total urine collection."( Recovery of absorptive function of the reticulo-rumen and total tract barrier function in beef cattle after short-term feed restriction.
Aschenbach, JR; Barreda, DR; Penner, GB; Zhang, S, 2013
)
0.39
"5 kg of wheat flour was orally dosed at 0 and 12 h of the experimental period to ACID, while the basal diet (grass hay, ad libitum) was restored to control."( Experimental acute rumen acidosis in sheep: consequences on clinical, rumen, and gastrointestinal permeability conditions and blood chemistry.
Ahmed, S; Bani, P; Bertoni, G; Jahan, N; Minuti, A; Piccioli-Cappelli, F; Trevisi, E, 2014
)
0.4
" Concentrations of BHB in vivo during subclinical ketosis did not alter the proliferative capability of bovine PBMC in vitro, which was first significantly decreased at a dosage of 5 mM BHB."( Effects of elevated parameters of subclinical ketosis on the immune system of dairy cows: in vivo and in vitro results.
Dänicke, S; Frahm, J; Kersten, S; Meyer, U; Reiche, D; Sauerwein, H; Schulz, K, 2015
)
0.42
" Under acute dosing conditions, the large size of an IR-binding antibody like XMetA (∼ 150 kDa) could lead to a more rapid access into liver, an insulin sensitive tissue with well-fenestrated capillaries, when compared to other insulin sensitive tissues with non-fenestrated capillaries, such as muscle and adipose."( Acute Treatment With XMetA Activates Hepatic Insulin Receptors and Lowers Blood Glucose in Normal Mice.
Adams, SH; Bedinger, DH; Goldfine, ID; Kieffer, DA; Roell, MK, 2015
)
0.42
" At time of calving, nine ruminally cannulated Holstein cows were randomly assigned to ruminal dosing of 500 g/d tap water (CON, n = 4) or 500 g/d PG (PPG, n = 5)."( Effect of postpartum propylene glycol allocation to over-conditioned Holstein cows on concentrations of milk metabolites.
Bjerre-Harpøth, V; Larsen, M; Larsen, T; Storm, AC; Vestergaard, M, 2016
)
0.43
" Myocardial insulin sensitivity was assessed as dose-response of Akt phosphorylation."( Impact of high-fat, low-carbohydrate diet on myocardial substrate oxidation, insulin sensitivity, and cardiac function after ischemia-reperfusion.
Douglas, SL; Liu, J; Lloyd, SG; Sham, S; Tate, JM; Wang, P, 2016
)
0.43
"Two experiments were conducted to characterize blood concentrations of minerals and acid-base status after oral dosing of Ca salts and to determine the effects of oral Ca on mineral and metabolic status and incidence diseases."( Effects of oral calcium supplementation on mineral and acid-base status, energy metabolites, and health of postpartum dairy cows.
Bisinotto, RS; Daetz, R; Galvão, KN; Lopera, C; Martinez, N; Risco, CA; Santos, JEP; Sinedino, LDP; Thatcher, WW, 2016
)
0.43
"Short-term intake of a high-fat diet aggravates postprandial glucose metabolism; however, the dose-response relationship has not been investigated."( Short-term high-fat diet alters postprandial glucose metabolism and circulating vascular cell adhesion molecule-1 in healthy males.
Endo, N; Kawano, H; Konishi, M; Numao, S; Sakamoto, S; Takahashi, M; Yamada, Y, 2016
)
0.43
" However, the effects of elevated butyrate concentrations on rumen metabolism have not been investigated, and consequently the maximum tolerable dosage rate of butyrate has not been established."( Single-dose infusion of sodium butyrate, but not lactose, increases plasma β-hydroxybutyrate and insulin in lactating dairy cows.
Casper, DP; Herrick, KJ; Hippen, AR; Kalscheur, KF; Moreland, SC; Schingoethe, DJ; van Eys, JE, 2017
)
0.46
"Considering the critical impacts of protein adsorption on NPs delivery, our work could be an urgent warning about the possible risks of dosage adjustment of nanoformulations."( Concentration-dependent protein adsorption at the nano-bio interfaces of polymeric nanoparticles and serum proteins.
Lu, BY; Peng, Q; Zhang, CL; Zhang, TX; Zhu, GY, 2017
)
0.46
" In conclusion, βHB did not improve high-intensity cycling or cognitive performance measures; however, these findings might be partially explained by the absolute dosing protocol used for βHB in the present study as opposed to a relative (g/kg) dosing protocol used in previous research."( Exogenous ketone salts do not improve cognitive responses after a high-intensity exercise protocol in healthy college-aged males.
Basham, SA; Chander, H; Knight, AC; Krings, BM; McAllister, MJ; Price, FG; Smith, JW; Waldman, HS, 2018
)
0.48
" In conclusion, a high dosage of rumen-protected NA reduced plasma β-hydroxybutyrate concentrations in cows during early lactation, but failed to cause an alteration in muscle fiber composition and muscle metabolic phenotype."( Effects of supplementing rumen-protected niacin on fiber composition and metabolism of skeletal muscle in dairy cows during early lactation.
Bolduan, C; Eder, K; Geyer, J; Koch, C; Most, E; Romberg, FJ; Weber, A; Windisch, W; Zeitz, JO, 2018
)
0.48
" Study 2: In a dose-response study, 8 HFrEF patients were examined at increasing 3-OHB infusion rates."( Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Bøtker, HE; Eiskjaer, H; Frøkiær, J; Gormsen, LC; Hansson, NH; Harms, HJ; Jespersen, NR; Lassen, TR; Mellemkjaer, S; Møller, N; Nielsen, R; Pryds, K; Sorensen, J; Tolbod, LP; Wiggers, H, 2019
)
0.51
" The pediatricians reported two limitations about blood 3HB dosage compared to the urinary test: the invasiveness of capillary blood collection, and the cost of supplies for finger pricking, reagent strips and reflectance meter."( Clinical utility of beta-hydroxybutyrate measurement in the management of physiological ketosis at home in children under 5.
Di Mauro, D; Dodi, I; Fainardi, V; Fanelli, U; Incerti, T; Iovane, B; Mastrorilli, C; Scarabello, C; Tchana, B; Vanelli, M; Veronese, P, 2019
)
0.51
" Results showed that at a dosing of 4 ppm of ECW, both chlorate and perchlorate concentrations in milk (<0."( Short communication: Effects of electrochemically activated drinking water on bovine milk production and composition, including chlorate, perchlorate, and fatty acid profile.
Ahrné, L; Dhakal, R; Hansen, HH; Nielsen, MO; Vargas-Bello-Pérez, E, 2020
)
0.56
" Nevertheless, specific dose-response relationships and safety margins of using D-3HB remain to be elucidated with more research."( On the nutritional and therapeutic effects of ketone body D-β-hydroxybutyrate.
Chen, GQ; Li, Z; Lyu, J; Wang, H; Wei, S; Xue, L; Yao, A; Yu, L, 2021
)
0.62
" This may relate to a combination of high concentrations of BHB (close to 2 mM) imposed systemically by spillover leading to high BHB concentrations in the saline-infused leg and a lack of major differences in concentration gradients between the two sides-implying that observations were made on the upper part of the dose-response curve for BHB and the relatively small number of subjects studied."( Investigating effects of sodium beta-hydroxybutyrate on metabolism in placebo-controlled, bilaterally infused human leg with focus on skeletal muscle protein dynamics.
Aagaard, R; Bach, E; Jessen, N; Johannsen, M; Jørgensen, JOL; Møller, N; Nielsen, BRR; Olesen, JF; Rittig, N; Svart, MV; Thomsen, HH; Voss, TS, 2022
)
0.72
"Effects of ketone supplements as well as relevant dose-response relationships and time effects on blood β-hydroxybutyrate (BHB), glucose and insulin are controversial."( Effects of ketone supplements on blood β-hydroxybutyrate, glucose and insulin: A systematic review and three-level meta-analysis.
Falkenhain, K; Kong, Z; Little, JP; Nie, J; Shi, Q; Wong, KK; Yu, Q, 2023
)
0.91
"This study aimed to summarize the existing evidence and synthesize the results, and demonstrate underlying dose-response relationships as well as sustained time effects."( Effects of ketone supplements on blood β-hydroxybutyrate, glucose and insulin: A systematic review and three-level meta-analysis.
Falkenhain, K; Kong, Z; Little, JP; Nie, J; Shi, Q; Wong, KK; Yu, Q, 2023
)
0.91
" Dose-response and time-effect models were established via fractional polynomial regression."( Effects of ketone supplements on blood β-hydroxybutyrate, glucose and insulin: A systematic review and three-level meta-analysis.
Falkenhain, K; Kong, Z; Little, JP; Nie, J; Shi, Q; Wong, KK; Yu, Q, 2023
)
0.91
" Nonlinear dose-response relationship between ketone dosage and blood parameter change was observed in some time intervals for BHB (30-60 min; >120 min) and insulin (30-60 min; 90-120 min), with linear relationship observed for glucose (>120 min)."( Effects of ketone supplements on blood β-hydroxybutyrate, glucose and insulin: A systematic review and three-level meta-analysis.
Falkenhain, K; Kong, Z; Little, JP; Nie, J; Shi, Q; Wong, KK; Yu, Q, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
pheromoneA semiochemical used in olfactory communication between organisms of the same species eliciting a change in sexual or social behaviour.
fungal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
3-hydroxybutyric acidA straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
ketone bodyA carbonyl compound produced as a water-soluble byproduct when fatty acids are broken down for energy in the liver. There are three endogenous ketone bodies: acetone, acetoacetic acid, and (R)-3-hydroxybutyric acid; others may be produced as a result of the metabolism of synthetic triglycerides.
3-hydroxy monocarboxylic acidA hydroxy monocarboxylic acid that has a hydroxy group beta to the carboxy group.
hydroxybutyric acidAny compound comprising a butyric acid core carrying at least one hydroxy substituent.
(omega-1)-hydroxy fatty acidA hydroxy fatty acid that is a straight-chain fatty acid in which one of the hydrogens attached to the carbon adjacent to the terminal methyl group (i.e. at the (omega-1) position) is replaced by a hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (15)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Ketone body metabolism1019
Synthesis of Ketone Bodies817
Ketone body catabolism410
Ketone Body Metabolism413
Succinyl CoA: 3-Ketoacid CoA Transferase Deficiency413
Butanoate metabolism ( Butanoate metabolism )1518
NAD+ + (R)-3-Hydroxy-butanoic acid = NADH + Acetoacetic acid ( Butanoate metabolism )14
Metabolism overview078
Amino acid metabolism094
Glucose homeostasis021
Fatty Acid Biosynthesis233
Disorders in ketone body synthesis512
Disorders in ketolysis58
Ketone bodies synthesis and degradation02

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency6.30960.044717.8581100.0000AID485294
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency28.18380.004611.374133.4983AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency79.43280.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 20Mus musculus (house mouse)Ki190.54601.10006.67899.1201AID360149
Solute carrier family 22 member 6Mus musculus (house mouse)Ki3,235.93990.40745.02179.4000AID360150
Protein skinhead-1Caenorhabditis elegansIC50 (µMol)100.00007.390021.523843.9000AID624474
Solute carrier family 22 member 20Mus musculus (house mouse)Ki190.77301.10006.67899.1201AID360149
Solute carrier family 22 member 6Mus musculus (house mouse)Ki3,227.97000.40745.02179.4000AID360150
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
lactate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
pyruvate catabolic processMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transportMonocarboxylate transporter 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
RNA bindingMonocarboxylate transporter 4Homo sapiens (human)
protein bindingMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
lactate:proton symporter activityMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
apical plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
lateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
nuclear membraneMonocarboxylate transporter 4Homo sapiens (human)
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID360150Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID360149Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID681140TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of physiology, Dec-01, Volume: 529 Pt 2Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle.
AID360151Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID1346306Mouse HCA2 receptor (Hydroxycarboxylic acid receptors)2005The Journal of biological chemistry, Jul-22, Volume: 280, Issue:29
(D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G.
AID1346416Human HCA2 receptor (Hydroxycarboxylic acid receptors)2005The Journal of biological chemistry, Jul-22, Volume: 280, Issue:29
(D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G.
AID681123TP_TRANSPORTER: inhibition of lactate uptake in Xenopus laevis oocytes1999The Biochemical journal, Aug-01, Volume: 341 ( Pt 3)Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes.
AID360151Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID681374TP_TRANSPORTER: inhibition of pyruvate uptake in Xenopus laevis oocytes1998The Journal of biological chemistry, Oct-30, Volume: 273, Issue:44
Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter.
AID360150Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID360149Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID679843TP_TRANSPORTER: inhibition of lactate uptake (Lactate:0.1mM, D,L-3-Hydroxybutyrate:50mM, preincubation with aminoxyacetate) in Xenopus laevis oocytes1997The Journal of biological chemistry, Nov-28, Volume: 272, Issue:48
Comparison of lactate transport in astroglial cells and monocarboxylate transporter 1 (MCT 1) expressing Xenopus laevis oocytes. Expression of two different monocarboxylate transporters in astroglial cells and neurons.
AID1754625Inhibition of K+ channel in LPS-primed mouse bone marrow derived macrophages assessed as inhibition of NLRP3 inflammasome activation-mediated IL-1beta release2021Bioorganic & medicinal chemistry letters, 08-15, Volume: 46Discovery of dronedarone and its analogues as NLRP3 inflammasome inhibitors with potent anti-inflammation activity.
AID682143TP_TRANSPORTER: inhibition of pyruvate uptake in Xenopus laevis oocytes1998The Journal of biological chemistry, Oct-30, Volume: 273, Issue:44
Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter.
AID681605TP_TRANSPORTER: change in intracellular pH(pHi)value in Xenopus laevis oocytes1998The Biochemical journal, Jul-01, Volume: 333 ( Pt 1)Characterization of the monocarboxylate transporter 1 expressed in Xenopus laevis oocytes by changes in cytosolic pH.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,483)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990772 (17.22)18.7374
1990's787 (17.56)18.2507
2000's817 (18.22)29.6817
2010's1373 (30.63)24.3611
2020's734 (16.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 51.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index51.43 (24.57)
Research Supply Index8.53 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index88.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (51.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials422 (9.08%)5.53%
Reviews0 (0.00%)6.00%
Reviews139 (2.99%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies76 (1.64%)4.05%
Observational0 (0.00%)0.25%
Observational21 (0.45%)0.25%
Other8 (100.00%)84.16%
Other3,988 (85.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]